A Study of Multiple Doses of LY2922470 in Participants With Diabetes
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the safety of LY2922470, taken as oral
capsules, once or twice daily for approximately 28 days, in participants with diabetes. It
also aims to determine how long the drug stays in the body and how it affects blood sugar
levels. A screening appointment is required within 28 days before the start of the study and
a follow up appointment is required approximately 14 days after the last study dose is taken.